Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Open Access
- 22 June 2012
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 12  (1) , 200
- https://doi.org/10.1186/1471-2407-12-200
Abstract
Advanced ovarian cancer is treated with cytoreductive surgery and combination platinum- and taxane-based chemotherapy. Although most patients have acute clinical response to this strategy, the disease ultimately recurs. In this work we questioned whether the synthetic steroid mifepristone, which as monotherapy inhibits the growth of ovarian cancer cells, is capable of preventing repopulation of ovarian cancer cells if given after a round of lethal cisplatin-paclitaxel combination treatment.This publication has 69 references indexed in Scilit:
- Caspase-3 and prostaglandins signal for tumor regrowth in cancer therapyOncogene, 2011
- Rethinking ovarian cancer: recommendations for improving outcomesNature Reviews Cancer, 2011
- Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapyNature Medicine, 2011
- Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2Investigational New Drugs, 2011
- Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinomaOncogene, 2010
- The biology of ovarian cancer: new opportunities for translationNature Reviews Cancer, 2009
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsPublished by Elsevier ,2006
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003